Cargando…

Atrial Fibrillation Cycle Length and Atrial Size in Horses with and without Recurrence of Atrial Fibrillation after Electrical Cardioversion

BACKGROUND: Atrial fibrillation (AF) cycle length (CL) and atrial size have been used in humans to characterize electrical and structural remodeling to predict outcome of cardioversion of AF and risk for AF recurrence (rAF). HYPOTHESIS: Atrial fibrillation cycle length can be determined in horses wi...

Descripción completa

Detalles Bibliográficos
Autores principales: De Clercq, D., Decloedt, A., Sys, S.U., Verheyen, T., Van Der Vekens, N., van Loon, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858013/
https://www.ncbi.nlm.nih.gov/pubmed/24611990
http://dx.doi.org/10.1111/jvim.12322
_version_ 1782430732731285504
author De Clercq, D.
Decloedt, A.
Sys, S.U.
Verheyen, T.
Van Der Vekens, N.
van Loon, G.
author_facet De Clercq, D.
Decloedt, A.
Sys, S.U.
Verheyen, T.
Van Der Vekens, N.
van Loon, G.
author_sort De Clercq, D.
collection PubMed
description BACKGROUND: Atrial fibrillation (AF) cycle length (CL) and atrial size have been used in humans to characterize electrical and structural remodeling to predict outcome of cardioversion of AF and risk for AF recurrence (rAF). HYPOTHESIS: Atrial fibrillation cycle length can be determined in horses with AF, and AFCL and atrial size are related to risk for rAF. ANIMALS: Eighteen horses with naturally occurring AF that were successfully converted to sinus rhythm (SR) by transvenous electrical cardioversion (TVEC). METHODS: Prospective study. Horses with severe valvular regurgitation, left atrial enlargement, or that required sedation for catheter placement were excluded. In all horses intra‐atrial electrograms were recorded and estimated AF duration and echocardiographic parameters were determined before TVEC. The follow‐up time was 1 year after TVEC. RESULTS: Atrial fibrillation cycle length could be determined in all horses. The AFCL and the shortest 5th percentile (p5) AFCL in horses with rAF (n = 6 or 33%) were (mean ± SD) 157 ± 28 and 134 ± 24 milliseconds, respectively, and in those maintaining SR (n = 12 or 67%) 166 ± 13 and 141 ± 13 milliseconds, respectively. Significant parameters to predict rAF were (1) the ratios of the p5AFCL to the left atrium (LA) sizes corrected to the size of aorta (AO) and (2) LA sizes corrected to the size of AO. CONCLUSIONS AND CLINICAL IMPORTANCE: Before TVEC, assessment of LA size and atrial electrophysiologic characteristics might help to identify horses at increased risk for AF recurrence.
format Online
Article
Text
id pubmed-4858013
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48580132016-06-22 Atrial Fibrillation Cycle Length and Atrial Size in Horses with and without Recurrence of Atrial Fibrillation after Electrical Cardioversion De Clercq, D. Decloedt, A. Sys, S.U. Verheyen, T. Van Der Vekens, N. van Loon, G. J Vet Intern Med Standard Articles BACKGROUND: Atrial fibrillation (AF) cycle length (CL) and atrial size have been used in humans to characterize electrical and structural remodeling to predict outcome of cardioversion of AF and risk for AF recurrence (rAF). HYPOTHESIS: Atrial fibrillation cycle length can be determined in horses with AF, and AFCL and atrial size are related to risk for rAF. ANIMALS: Eighteen horses with naturally occurring AF that were successfully converted to sinus rhythm (SR) by transvenous electrical cardioversion (TVEC). METHODS: Prospective study. Horses with severe valvular regurgitation, left atrial enlargement, or that required sedation for catheter placement were excluded. In all horses intra‐atrial electrograms were recorded and estimated AF duration and echocardiographic parameters were determined before TVEC. The follow‐up time was 1 year after TVEC. RESULTS: Atrial fibrillation cycle length could be determined in all horses. The AFCL and the shortest 5th percentile (p5) AFCL in horses with rAF (n = 6 or 33%) were (mean ± SD) 157 ± 28 and 134 ± 24 milliseconds, respectively, and in those maintaining SR (n = 12 or 67%) 166 ± 13 and 141 ± 13 milliseconds, respectively. Significant parameters to predict rAF were (1) the ratios of the p5AFCL to the left atrium (LA) sizes corrected to the size of aorta (AO) and (2) LA sizes corrected to the size of AO. CONCLUSIONS AND CLINICAL IMPORTANCE: Before TVEC, assessment of LA size and atrial electrophysiologic characteristics might help to identify horses at increased risk for AF recurrence. John Wiley and Sons Inc. 2014-02-24 2014 /pmc/articles/PMC4858013/ /pubmed/24611990 http://dx.doi.org/10.1111/jvim.12322 Text en Copyright © 2014 by the American College of Veterinary Internal Medicine
spellingShingle Standard Articles
De Clercq, D.
Decloedt, A.
Sys, S.U.
Verheyen, T.
Van Der Vekens, N.
van Loon, G.
Atrial Fibrillation Cycle Length and Atrial Size in Horses with and without Recurrence of Atrial Fibrillation after Electrical Cardioversion
title Atrial Fibrillation Cycle Length and Atrial Size in Horses with and without Recurrence of Atrial Fibrillation after Electrical Cardioversion
title_full Atrial Fibrillation Cycle Length and Atrial Size in Horses with and without Recurrence of Atrial Fibrillation after Electrical Cardioversion
title_fullStr Atrial Fibrillation Cycle Length and Atrial Size in Horses with and without Recurrence of Atrial Fibrillation after Electrical Cardioversion
title_full_unstemmed Atrial Fibrillation Cycle Length and Atrial Size in Horses with and without Recurrence of Atrial Fibrillation after Electrical Cardioversion
title_short Atrial Fibrillation Cycle Length and Atrial Size in Horses with and without Recurrence of Atrial Fibrillation after Electrical Cardioversion
title_sort atrial fibrillation cycle length and atrial size in horses with and without recurrence of atrial fibrillation after electrical cardioversion
topic Standard Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858013/
https://www.ncbi.nlm.nih.gov/pubmed/24611990
http://dx.doi.org/10.1111/jvim.12322
work_keys_str_mv AT declercqd atrialfibrillationcyclelengthandatrialsizeinhorseswithandwithoutrecurrenceofatrialfibrillationafterelectricalcardioversion
AT decloedta atrialfibrillationcyclelengthandatrialsizeinhorseswithandwithoutrecurrenceofatrialfibrillationafterelectricalcardioversion
AT syssu atrialfibrillationcyclelengthandatrialsizeinhorseswithandwithoutrecurrenceofatrialfibrillationafterelectricalcardioversion
AT verheyent atrialfibrillationcyclelengthandatrialsizeinhorseswithandwithoutrecurrenceofatrialfibrillationafterelectricalcardioversion
AT vandervekensn atrialfibrillationcyclelengthandatrialsizeinhorseswithandwithoutrecurrenceofatrialfibrillationafterelectricalcardioversion
AT vanloong atrialfibrillationcyclelengthandatrialsizeinhorseswithandwithoutrecurrenceofatrialfibrillationafterelectricalcardioversion